GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (FRA:6K9) » Definitions » YoY EPS Growth

Context Therapeutics (FRA:6K9) YoY EPS Growth : 43.32% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Context Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2024 was 43.32%.

Context Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €-0.21.

Context Therapeutics YoY EPS Growth Historical Data

The historical data trend for Context Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Context Therapeutics YoY EPS Growth Chart

Context Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
- -16.52 -397.87 73.12 -56.61

Context Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -87.00 -20.68 -43.39 -85.10 43.32

Context Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Context Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-1.375--0.878)/ | -0.878 |
=-56.61 %

Context Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EPS Growth (Q: Mar. 2024 )
=(Earnings per Share (Diluted) (Q: Mar. 2024 )-Earnings per Share (Diluted) (Q: Mar. 2023 )) / | Earnings per Share (Diluted) (Q: Mar. 2023 )) |
=(-0.212--0.374)/ | -0.374 |
=43.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Context Therapeutics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Context Therapeutics (FRA:6K9) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (FRA:6K9) » Definitions » YoY EPS Growth
Comparable Companies
NTRB AZTR KALA MYMD LSTA ICU AXLA EQ COCP MBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CNTX:USA 6K9:Germany
Address
2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Website
https://www.contexttherapeutics.com
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.

Context Therapeutics (FRA:6K9) Headlines

No Headlines